Cargando…
NASH limits anti-tumour surveillance in immunotherapy-treated HCC
Hepatocellular carcinoma (HCC) can have viral or non-viral causes(1–5). Non-alcoholic steatohepatitis (NASH) is an important driver of HCC. Immunotherapy has been approved for treating HCC, but biomarker-based stratification of patients for optimal response to therapy is an unmet need(6,7). Here we...
Ejemplares similares
-
Specificity, propagation, and memory of pericentric heterochromatin
por: Müller-Ott, Katharina, et al.
Publicado: (2014) -
Epigenetic signals that direct cell type–specific interferon beta response in mouse cells
por: Muckenhuber, Markus, et al.
Publicado: (2023) -
NAFLD and cardiovascular diseases: a clinical review
por: Kasper, Philipp, et al.
Publicado: (2020) -
Local Control after Locally Ablative, Image-Guided Radiotherapy of Oligometastases Identified by Gallium-68-PSMA-Positron Emission Tomography in Castration-Sensitive Prostate Cancer Patients (OLI-P)
por: Hölscher, Tobias, et al.
Publicado: (2022) -
Programmed cell death protein‐1 (PD‐1)‐targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real‐world cohort
por: Scheiner, Bernhard, et al.
Publicado: (2019)